CVS Health (CVS)
(Delayed Data from NYSE)
$66.63 USD
-0.22 (-0.33%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $66.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.63 USD
-0.22 (-0.33%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $66.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth C Momentum B VGM
Zacks News
Americans on a Spring Spending Spree: Top 5 Gainers
by Tirthankar Chakraborty
Big burst of spending in spring after a ho-hum winter is primarily backed by Trump's tax cuts, strong hiring and declining unemployment rate.
Buy Walgreens (WBA) Stock Because It's Cheap & Amazon Fears Are Overblown?
by Benjamin Rains
Shares of Walgreens Boots Alliance (WBA) are down 16.5% over the last year based mostly on Amazon (AMZN) fears. There is no doubt that online selling and delivery have altered the retail world, but does that mean Walgreens can no longer compete? Let's dive into some of WBA's fundamentals to see what to do with the stock.
4 Retail Stocks to Buy as Q2 Earnings Season Knocks
by Sumit Singh
Search for safe havens has intensified ever since the trade hostility between the United States and China commenced. However, its high time that you bury the trade related fears and rejig your portfolio.
Trade Wars and Recessions: What Should Investors Do?
by Tracey Ryniec
The best thing investors can do is have a plan. Find out where you should be investing in this uncertain market.
Amazon Forays Into Pharmacy Business: Red Alert for Others?
by Sweta Jaiswal
Amazon's entry into the high-potential pharmaceutical industry deals a blow to share prices of major players.
Will Healthcare Buck Up on Amazon's Pillpack Takeover Deal?
by Sapna Bagaria
Amazon's (AMZN) use of technology, innovative strategies and skilled leadership should take it far in the healthcare space.
NKE Beats Earnings, Spotify's Video Push, & AMZN's Big Pharma Purchase
by Madeleine Johnson
On today's episode of the Zacks Friday Finish Line, Editor Maddy Johnson is joined by Ben Rains, an Associate Stock Strategist here at Zacks, to take on this week's biggest stories, including Nike's latest quarterly earnings results, Spotify's media ambitions, and Amazon's latest assault on the healthcare industry.
After a Historic Rise, Should You Still Buy Amazon (AMZN) Stock?
by Afrasiab Mian
With massive growth already baked into its stock price, many investors may feel that Amazon stock is too expensive and that they have missed their chance to cash in. Is this truly the case? Let's take a look.
Investors Shouldn't Panic About Amazon's PillPack Purchase
by Benjamin Rains
Shares of pharmacy giants CVS (CVS), Rite Aid (RAD), and Walgreens Boots Alliance (WBA) all plummeted on Thursday morning after Amazon (AZMN) announced its purchase of online pharmacy delivery startup PillPack. The move clearly has some investors worried that Amazon's push into the pharmaceutical industry will hurt the current powers. So let's take a look at more of the details to find out what's really going on.
Want to Tap Merger Mania? Play Top-Ranked Health Care ETFs
by Sanghamitra Saha
What is driving Healthcare merger-mania and how to tap it with ETFs.
Rite Aid-Albertsons Deal: US SEC Sanctions Proxy Materials
by Zacks Equity Research
Rite Aid (RAD) is moving closer to completing its previously announced merger with Albertsons. The company's shareholders are going to cast their votes regarding the deal on Aug 9.
Should You Buy Grocery Stocks, WMT, COST, TGT, After Kroger's Strong Quarter?
by Benjamin Rains
Shares of Kroger (KR) surged over 10% on Thursday to inch near their 52-week high after the company posted better-than-expected quarterly results. Investors were also likely pleased to see that the grocery chain's e-commerce initiatives started to pay off. The question is should investors think about buying grocery stocks as Amazon-based (AMZN) fears seem to have been overblown.
Walgreens-GE Faceoff: How Impactful is it for Dow Investors?
by Urmimala Biswas
The stock performance of Walgreens Boots (WBA) currently does not offer much conviction. Over the past year, shares show a decline of 17.9%.
Humana, Walgreens Team Up to Provide Better Senior Care
by Zacks Equity Research
Humana (HUM) ties up with Walgreens to provide better primary care and other services to seniors of the Kansas City Community.
Anthem Boosts Integrated Care With Aspire Health Buyout
by Zacks Equity Research
Anthem's (ANTM) acquisition of Aspire Health points to its increased efforts in comprehensive community-based palliative care space.
One Year After Amazon Bought Whole Foods, Who's Winning the Grocery War?
by Benjamin Rains
Amazon (AMZN) might have forever changed the grocery industry exactly one year ago when the e-commerce giant bought Whole Foods for roughly $14 billion on June 16, 2017. Today, grocery delivery is commonplace across the entire industry.
Should Value Investors Consider CVS Health (CVS) Stock Now?
by Zacks Equity Research
CVS Health (CVS) appears to be a good choice for value investors right now, given its favorable P/E and P/S metrics.
Medical Device Industry Outlook - June 2018
by Zacks Equity Research
The medical device industry's global annual sales is forecast to rise more than 5% a year to reach nearly $800 billion by 2030.
Express Scripts' Inside Rx to Cut Medical Costs for the Aged
by Zacks Equity Research
Express Scripts (ESRX) keeps its commitment towards patient benefit management through subsidiary Inside Rx.
Health Insurance Industry Outlook - May 2018
by Zacks Equity Research
Higher medical enrollment, surging revenues, medical cost management and an increasing share of revenues from complementary services helped results.
Fred's Confirms Sale of Specialty Pharmacy Unit, Stock Up
by Zacks Equity Research
Fred's (FRED) implements its long-standing plans to divest specialty pharmacy segment to CVS Health Corporation.
Fred's (FRED) Q4 Loss Widens Year Over Year, Stock Loses 6%
by Zacks Equity Research
Fred's (FRED) continues to struggle with its front store business. However, the company remains focused on turnaround.
CVS Health (CVS) Beats on Q1 Earnings, Revenues Lag Estimate
by Zacks Equity Research
CVS Health (CVS) witnessed year-over-year growth in Pharmacy Services Segment on the back of growth in pharmacy network and specialty pharmacy volume as well as brand inflation.
Fred's Stock Jumps Over 13% in a Day, 2 Things You Must Note
by Zacks Equity Research
Fred's (FRED) has rescheduled its earnings announcement date.This is solely connected to Fred's plans to divest its specialty pharmacy business.
Why Are Walgreens and CVS Shares Surging Today?
by Ryan McQueeney
Shares of several major pharmaceutical retailers--including Walgreens (WBA) and CVS Health (CVS)--surged in afternoon trading Monday after reports emerged that e-commerce behemoth Amazon (AMZN) has shelved its plan to sell prescription drugs to doctors and hospitals.